IT injections of AntagoNATs targeted against SCN1A NAT induced an increase in SCN1A levels in the brain of mice and nonhuman primates (Hsiao et al., 2016; Dravet Syndrome). This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.